RAD June 2021 Virtual Conference Abstracts & Posters

Abstracts have been published in the September 2021 issue of the British Journal of Dermatology and can be found here: https://onlinelibrary.wiley.com/doi/10.1111/bjd.20648.

#505 - Comparison of Efficacy of Targeted Therapies without Topical Corticosteroids for Moderate to severe Atopic Dermatitis: Systematic Review and Network Meta-analysis

Jonathan I. Silverberg; H. Chih-ho Hong; Jacob P. Thyssen; Brian M. Calimlim; Avani D. Joshi; Henrique D. Teixeira; Eric B. Collins; Marjorie M. Crowell5; Scott J. Johnson; April W. Armstrong


#506 - Achieving Incrementally Greater Skin Improvement Thresholds with Upadacitinib in Moderate to Severe Atopic Dermatitis: A Pooled Analysis of Two Phase 3 Studies (Measure Up 1 and Measure Up 2)

Kristian Reich, Richard G. Langley, Brian M. Calimlim, Henrique D. Teixeira, Jiewei Zeng, Jonathan I. Silverberg


#508 - Rapid and sustained improvements in itch and sleep with tralokinumab treatment in patients with moderate-to-severe Atopic Dermatitis, a post hoc analysis of pooled data from ECZTRA 1 and 2

Eric Simpson, Andreas Wollenberg, Weily Soong, Thomas Mark, Alexandra Kuznetsova, Louise Abildgaard-Steffensen, Jonathan I Silverberg


#509 - Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post hoc subgroup analysis from ECZTRA 7 trial

Jan Gutermuth, Andrew Pink, Margitta Worm, Lise Soldbro, Thomas Mark, Joshua Corriveau, Christian Bjerregård Øland, Stephan Weidinger


#510 - Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis (AD) From the Phase 2 and Phase 3 Clinical Trial Program

Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum, Kevin Winthrop, Emma Guttman-Yassky, Karin M. Hoffmeister, Min Zhang, Saleem A. Farooqui, Susan Johnson, Andrew Thorpe, Ricardo Rojo


#511 - Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies

Kim Papp, MD, PhD, Jacek C. Szepietowski, MD, PhD, FRCP (Edin), Leon Kircik, MD, Darryl Toth, MD, Lawrence F. Eichenfield, MD, Seth B. Forman, MD, Michael E. Kuligowski, MD, PhD, MBA, May E. Venturanza, MD, Kang Sun, PhD, Eric L. Simpson, MD, MCR


#512 - Real-World Effectiveness of Systemic Therapies for Atopic Dermatitis (AD) in the United States: Analysis of a Retrospective Claims Database

Marco DiBonaventura, Marie-Helene Lafeuille, Bruno Emond, Mei Sheng Duh, Iman Fakih, Natalie Yin, Daniela E. Myers, Claire Feeney, Joseph C. Cappelleri, Jashin J. Wu


#513 - Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies

Eric L. Simpson, MD, MCR, Leon Kircik, MD, Andrew Blauvelt, MD, MBA, Michael E. Kuligowski, MD, PhD, MBA, May E. Venturanza, MD, Kang Sun, PhD, Lawrence F. Eichenfield, MD


#514 - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 2a Study to Evaluate the Mechanism of Action of Abrocitinib Monotherapy for Moderate-to-Severe Atopic Dermatitis (JADE MOA)

Emma Guttman-Yassky, Robert Bissonnette, Seth Forman, Karen Page, Ricardo Rojo, Hedieh Saffari, Svitlana Y. Tatulych, David Williams April Armstrong


#515 - Long-Term Safety and Disease Control With Ruxolitinib Cream Among Patients With Atopic Dermatitis Based on Previous Medication History: Pooled Results From Two Phase 3 Studies

Andrew Blauvelt, MD, MBA, Lawrence F. Eichenfield, MD, Michael E. Kuligowski, MD, PhD, MBA, May E. Venturanza, MD, Kang Sun, PhD, Jonathan I. Silverberg, MD, PhD, MPH


Page 5 of 7
Results 41 - 50 of 65
© 2022 The Foundation for Dermatology Education.
The Foundation for Dermatology Education is a registered 501(c)(3) nonprofit organization located in Chicago, IL.